53 results about "Erythrocytes membrane" patented technology

The invention discloses a construction method and application of a ratio-dependent electrochemical luminescence (ECL) biosensor based on an antifouling red cell membrane, and belongs to the technical fields of photoelectric analysis, biosensing and interface antifouling. In the invention, the erythrocyte membrane with super-hydrophilicity and low membrane protein content is used as an efficient antifouling interface, and the good biocompatibility of the erythrocyte membrane avoids the influence of a chemical antifouling coating on the biological activity of the ECL sensor. Meanwhile, the electropolymerized polyaniline nanowire is embedded into the antifouling erythrocyte membrane, so that the chemical stability and the conductivity of the antifouling erythrocyte membrane are enhanced, and the application of the antifouling erythrocyte membrane in ECL analysis is expanded. C3N4 is introduced as an interior label for eliminating background signals and external interference, so that the detection precision of the biosensor is improved. On the basis, the constructed ECL antifouling biosensor realizes ultra-sensitive detection of human breast cancer cells MCF-7 in human serum, and the detection limit is as low as 3 cells / mL.

The invention belongs to the technical field of cell engineering and biochemical detection, and particularly relates to an erythrocyte membrane with a complete structure and a preparation method and application thereof. The red blood cells are split by limiting the components of the release liquid, the conditions are mild, protein components such as hemoglobin in the red blood cells can be released, the cell attributes are removed, the integrity of the internal skeleton structure and the activity of the membrane surface antigen are reserved, the complete structure of the red cell membrane is kept, meanwhile, the key blood group antigen on the surface is reserved, and the effect is good. The problem of antigenicity reduction caused by erythrocyte membrane fragmentation is avoided. After the erythrocytes are lysed, the nanoparticles are coupled to the surface of the erythrocyte membrane, so that the agglutination reaction of the erythrocyte membrane under the induction of the antibody can be visualized. The engineering red blood cell biological membrane is preserved by adopting a fixed program, so that the damage of ice crystals to the engineering red blood cell biological membrane can be effectively avoided, the antigenicity of the membrane is not influenced, the membrane can be preserved for a long time at normal temperature, and the shelf life can be prolonged to two years or more.

The invention discloses an artificial blood vessel and a preparation method thereof, and the preparation method comprises the following steps: uniformly mixing an erythrocyte ghost suspension and melanin nanoparticles to obtain a mixed solution; carrying out ultrasonic treatment and extrusion on the mixed solution to obtain a melanin nano-vesicle solution; carrying out electrostatic spinning on the polycaprolactone solution to obtain a polycaprolactone electrostatic spinning blood vessel; soaking the polycaprolactone electrostatic spinning blood vessel in an ethylenediamine solution, and then washing the polycaprolactone electrostatic spinning blood vessel with a phosphate buffer solution; then soaking in a 4-morpholine ethanesulfonic acid solution; finally, carrying out heparinization in a 4-morpholine ethanesulfonic acid solution containing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and heparin; and incubating the heparin-modified polycaprolactone electrostatic spinning blood vessel in the melanin nano-vesicle solution to obtain the artificial blood vessel. The melanin nano-vesicles are modified, so that the anticoagulation performance of erythrocyte membranes is reserved, and meanwhile, the scavenging capacity of melanin nano-particles on reactive oxygen free radicals is reserved.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The invention discloses an artificial blood vessel and a preparation method thereof, and relates to the technical field of artificial materials. The artificial blood vessel comprises a polymer spinning blood vessel base; the polymer coating with positive charges is attached to the surface of the polymer spinning blood vessel substrate; and the erythrocyte membrane vesicles of the eversion phosphatidylserine are attached to the surface of the positively charged polymer coating through electrostatic adsorption. The artificial blood vessel provided by the invention can inhibit blood vessel restenosis by virtue of the immune regulation and control capability of phosphatidylserine, and finally the long-term patency rate of the artificial blood vessel is improved.

The invention discloses bionic nanoparticles, a composition, a preparation method and application thereof, and relates to the technical field of red blood cell-cancer cell hybrid membrane bionics. The bionic nanoparticles comprise lipidosome and a hybrid membrane coated on the surface of the lipidosome, drugs are coated in the lipidosome, and the drugs are astragaloside and curcumin; the molar ratio of the medicine to the liposome is 1: 15; the hybrid membrane is a hybrid membrane of an erythrocyte membrane and a cancer cell membrane. The erythrocyte-cancer cell hybrid membrane wraps the outer layer of the liposome phospholipid bilayer to construct the nano targeting drug delivery system, the modification of the hybrid cell membrane integrates the advantages of long circulation, immune escape, homologous targeting and the like, and a new treatment mode is developed for immunotherapy of malignant tumors with low response rate. The hybrid membrane can improve the targeting property of the drug, reduce side effects on patients and improve the tolerance of the patients. The medicine can be coated in an aqueous solution layer of the liposome, so that the water solubility of the medicine is improved, and meanwhile, the anti-tumor effect of the medicine can be enhanced.

The invention discloses a spleen-targeted nano platform construction method suitable for tumor vaccination, and particularly relates to the field of vaccines.The spleen-targeted nano platform construction method comprises the steps that S1, CL15H6-DOPS LNPs, spherical polymer vesicles and erythrocyte membrane coated nano-particles are selected as spleen-targeted nano-carriers; s2, integrating an immunologic adjuvant; mn < 2 + > doped LNPs, ultrasonic response lipidosome and a CD3 antibody are selected to be coupled to serve as an integration material; s3, delivering in vivo; animal models are selected for in-vivo delivery and curative effect verification, and B16F10 melanoma mice, MC38 colon cancer mice and non-human primates are selected as the animal models respectively. By optimizing the chain length and the surface topological structure (such as spherical polymer vesicles) of the liposome, the spleen enrichment rate is remarkably increased, and the red marrow myeloid cell uptake efficiency is enhanced. By combining with common delivery of a manganese adjuvant, an STING channel is activated, secretion of type I interferon is promoted, and the proportion of antigen-specific CD8 + T cells and the tumor inhibition rate are increased.

The invention discloses a red blood cell room-temperature preservation solution as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The erythrocyte preservative comprises the following components in parts by weight: 1-200 parts of an anticoagulant, 1-200 parts of a blood cell stabilizer, 1-100 parts of a metabolic inhibitor, 1-100 parts of an electrolyte, 1-150 parts of an antioxidant and 350-1000 parts of deionized water, and the pH value of the erythrocyte preservative is 4.6-7.0. All the components in the preservative are mutually matched and have a synergistic effect, and the integrity of erythrocyte membranes can be kept through synergistic protection of the multiple components; the electrolyte equilibrium osmotic pressure is maintained, the antioxidant scavenges free radicals, and hemolysis is reduced; the preservation time is prolonged, and the cell morphology and function are good; the dependence on a cold chain is reduced, and the demand on deep hypothermia equipment is reduced.

The invention discloses a targeting nano material covering an erythrocyte membrane as well as a preparation method and application of the targeting nano material covering the erythrocyte membrane. The targeting nano material covering the erythrocyte membrane comprises a metal organic framework material, the surface of the metal organic framework material is coated with the erythrocyte membrane; the aptamer is connected with the outer surface of the erythrocyte membrane; the aptamer is Apt19S, and the nucleotide sequence of the aptamer is as shown in SEQ ID NO. 1. The nano material provided by the invention has good stability and targeting performance, can specifically recruit bone marrow mesenchymal stem cells to participate in osteogenic differentiation, and can be used as a novel nano material for promoting bone regeneration.

The invention relates to dual-targeting bionic hydrotalcite inorganic nanoparticles as well as a preparation method and application thereof. The preparation method comprises the following steps: obtaining a fresh erythrocyte membrane; obtaining an aged erythrocyte membrane; adding a fresh erythrocyte membrane and an aged erythrocyte membrane into the hydrotalcite inorganic nano-particles according to a certain proportion, mixing and stirring, and centrifuging to obtain the bionic hydrotalcite inorganic nano-particles. The dual-targeting bionic hydrotalcite inorganic nano-particles have the beneficial effects that the dual-targeting bionic hydrotalcite inorganic nano-particles have dual-targeting capability of being delivered to parenchymal hepatic cells and hepatic macrophages in a balanced manner, and oxidative stress and inflammatory response can be relieved at the same time.

In the first aspect, at least one of phosphatidylinositol 4-kinase type 2 alpha, phosphatidylinositol 5-phosphate 4-kinase type 2 alpha and protein kinase C beta is used as a marker to prepare a detection reagent or a kit so as to realize diagnosis or auxiliary diagnosis of Parkinson's disease. The kinases detected in an erythrocyte membrane as the PD diagnosis marker have the following advantages: 1, hemoglobin interference can be effectively removed through hypotonic lysis / centrifugal separation, the detection stability is improved, and accurate discovery of the marker is facilitated; 2, the erythrocyte membrane is easy to obtain and noninvasive, so that great convenience is provided for popularization of detection; 3, the biomarker found based on the erythrocyte membrane can be popularized or combined with serum detection, and it is possible to efficiently and stably detect PD.

The invention discloses a borneol modified erythrocyte membrane coated dendritic macromolecule bionic nano drug delivery system and preparation and application thereof, the bionic nano drug delivery system comprises an erythrocyte membrane and a drug loaded dendritic macromolecule coated in the erythrocyte membrane, the surface of the erythrocyte membrane is modified with targeted molecule borneol, the drug is an anti-tumor drug, such as bufotalin. In combination with a nasal drop administration mode, not only can the brain targeting efficiency of the glioma treatment drug be improved, but also the glioma treatment drug has immune escape and tumor microenvironment response capabilities, the in-vivo circulation time of the drug is effectively prolonged, and the glioma treatment effect is further improved. The design that the dendritic macromolecules are coated with the modified erythrocyte membranes combines the biocompatibility of natural cell membranes and the multifunctionality of nanoparticles, and the dendritic macromolecules have huge application potential in the fields of drug delivery, immune regulation, detoxification, targeted therapy and the like.

The invention relates to the technical field of biological medicine, in particular to DNase I loaded lipidosome and application thereof. The invention provides a bionic long-acting deoxyribonuclease I (DNase I) liposome with free DNA (cfDNA) responsiveness and a dual-targeting function, the liposome is subjected to layered fusion modification through an erythrocyte membrane and a neutrophile granulocyte membrane, a release window is accurately regulated and controlled by utilizing a 4ME-PC proportion, and a liposome drug carrier for cfDNA targeted combination and accurate delivery of an inflammation part is realized. The polypeptide can be used for cfDNA-related inflammatory diseases, and has an important application prospect.

The invention is applicable to the technical field of synthetic biology and membrane bioengineering, and provides a fusion membrane system for constructing an artificial organelle and a construction method thereof, the fusion membrane system comprises: a pigment body membrane for light-driven ATP synthesis; the erythrocyte membrane is used for consuming ATP to drive ion transport; the fusion promoting component comprises cholesterol-PEG (Polyethylene Glycol)-(EIAALEK) 4 and cholesterol-PEG-(KIAALKE) 4; the pigmented body membrane and the erythrocyte membrane form a fused vesicle structure under the action of the fusion promoting component. The steps of protein purification and artificial lipid assembly are avoided, the operation process is simplified, functional recombination of a heterologous natural membrane protein module is achieved, an energy-self-sufficiency artificial organelle is constructed, the ATP utilization efficiency is remarkably higher than that of a physical mixed membrane system and is improved by about 2-3 times, and the application prospect is wide. And a feasible framework is provided for energy management and artificial organelle design in a synthetic biological system.

The invention discloses bionic MOFs of red blood cells as well as a preparation method and application of the bionic MOFs, and belongs to the technical field of biological materials. Comprising drug-loaded MOFs and an erythrocyte membrane layer coated outside the MOFs, the MOFs is selected from the group consisting of UiO-66-NH2; the UiO-66-NH2 is a particle formed by connecting an amino functional group to UiO-66; a dual epigenetic drug is loaded in the drug-loaded MOFs; and the dual epigenetic drugs are CM272 and MA. By targeting three epigenetic modifications and simultaneously regulating and controlling DNA methylation, histone methylation and RNA methylation in leukemia cells, the immune response aiming at acute myelogenous leukemia is enhanced, the hypoxia microenvironment of leukemia is overcome by using the bionic MOFs particles, the therapeutic activity of the loaded medicine is enhanced, and the application prospect is broad. And inducing death of leukemia cells and leukemia cell mesenchymal stem cells.

The present disclosure proposes a preparation method of a vesicle formed by an erythrocyte membrane encapsulating Newcastle disease virus, including: mixing a compacted erythrocyte solution, a phosphate buffered saline (PBS) solution, and Newcastle disease virus (NDV); centrifuging a resulting mixture of erythrocytes added with NDV; and resuspending and precipitating the centrifuged mixture with a PBS solution to obtain the vesicle formed by the erythrocyte membrane encapsulating Newcastle disease virus.

The invention provides a CRISPR-Cas9 near-infrared two-region precise light-operated editing system delivery carrier based on an erythrocyte membrane, a preparation method and application, and particularly, the CRISPR-Cas9 gene editing system delivery carrier provided by the invention has the advantages of low cytotoxicity, efficient transfection, high yield, targeting property, space-time controllability, easiness in large-scale production and multifunctionality. Compared with a traditional liposome transfection reagent, the carrier shows lower cytotoxicity, protects the CRISPR / Cas9 compound from being influenced by the in-vivo environment, and ensures that the CRISPR / Cas9 compound is smoothly delivered to target cells. By embedding a specific targeting receptor, efficient targeting delivery is realized, and the pertinence and effectiveness of treatment are improved. And by combining a near-infrared two-region material, the time-space precise control of a CRISPR / Cas9 system is realized, and deeper tissue penetrating power and smaller biotoxicity are achieved. The preparation process is simple, the method is suitable for industrial production and clinical transformation, and new possibility is provided for gene therapy and personalized medical treatment.

The invention relates to the field of cancer treatment, and particularly discloses a synthetic method and application of a dual-response bimetallic nano-catalyst, and the synthetic method comprises the following steps: 1, synthesizing CuFeMOF nanoparticles; (2) synthesizing CuFeMOF (at) GOx nano particles; step 3, synthesizing a CuFeMOF (at) GOx (at) Mem) nano particle structure catalyst; under the action of an erythrocyte membrane, after the CuFeMOF (at) GOx (at) Mem is accumulated in a tumor tissue, GOx catalyzes glucose to generate H2O2 and gluconic acid, the gluconic acid aggravates reduction of PH in the tissue, the CuFeMOF (at) GOx (at) Mem is further activated to release Fe < 3 + > and Cu < 2 + >, then the Fe < 3 + > and the Cu < 2 + > are converted into Fe < 2 + > and Cu < + > by GSH, and Fe < 2 + >-mediated Fenton reaction is activated; in addition, Cu < + > can further promote conversion from Fe < 3 + > to Fe < 2 + >, and the CDT (chemodynamic therapy) effect is enhanced. The capacity of continuously accumulating Fe < 2 + > and eliminating GSH is shown through the amplification effect among GSH, Fe and Cu ions. In conclusion, according to the nano system, the effect of the CDT is greatly improved through a triple regulation mechanism of H2O2 self-supply, catalyst self-circulation and GSH self-elimination, and a unique method is provided for improving the anti-tumor potential of the CDT.

The invention relates to the field of anti-tumor drugs, and discloses a nano medical drug taking FABP5 as a target as well as a preparation method and application of the nano medical drug. The nano medical drug is prepared by integrating a lipid nano shell with pH response, cycloarginine-glycine-aspartic acid and an erythrocyte membrane, and encapsulating nano particles of superparamagnetic iron oxide and sgFABP5. The nano medical medicine has the application potential of synergistically enhancing the tumor treatment effect after the liver cancer radiofrequency ablation operation.

This invention relates to the field of antibody drug technology, and more particularly to a human recombinant single-chain antibody, nanoparticles, and nanomedicine compositions and their applications. This invention provides a human recombinant single-chain antibody specifically targeting PHD2, the amino acid sequence of which is shown in SEQ ID NO:2. The human recombinant single-chain antibody obtained by this invention is more stable than INP and exhibits better organ and tissue targeting. Combining this human recombinant single-chain antibody with mesoporous silica nanoparticles and erythrocyte membranes to prepare a nanomedicine composition, this nanomedicine composition has better therapeutic efficacy.

A polypeptide specifically binding to an erythrocyte membrane or a mutant thereof. The polypeptide or mutant thereof can be fused with various recombinant proteins. By using the binding property of the polypeptide or mutant thereof to erythrocytes and dynamically balancing the binding to and releasing from an erythrocyte membrane, the sustained release of a drug can be achieved, thereby prolonging the circulation half-life of the drug.

The invention relates to bionic iron-based nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of cell membrane camouflage nanoparticles. The bionic iron-based nano-particles comprise drug-loaded Fe3O4 nano-particles and red cell membranes compounded on the surfaces of the drug-loaded Fe3O4 nano-particles, and the red cell membranes are modified by galactose. The preparation method comprises the following steps: S1, mixing an ethanol solution of emodin with an ethanol dispersion liquid of hollow Fe3O4 nanoparticles, centrifuging, discarding a supernatant, and carrying out vacuum drying; s2, suspending the erythrocyte membrane in a buffer solution, and adding galactose for incubation; and S3, mixing the drug-loaded Fe3O4 nanoparticles with the galactose modified erythrocyte membrane, and enveloping to obtain the bionic iron-based nanoparticles. According to the invention, the nanoparticles wrapped by the erythrocyte membrane can reduce the removal of the nanoparticles by an immune system; the nano-particles can be effectively transferred into the M2TAMs by the galactose modified erythrocyte membrane, the emodin is released in the M2TAMs, and the emodin and the hollow Fe3O4 nano-particles cooperate to reprogram the M2TAMs.

The invention discloses a construction method and application of a ratio-type electrochemiluminescence (ECL) biosensor based on an anti-fouling erythrocyte membrane, belonging to the technical fields of optoelectronic analysis, biosensing, and interfacial anti-fouling. In the present invention, an erythrocyte membrane with super-hydrophilicity and low membrane protein content is used as an efficient anti-fouling interface, and its good biocompatibility avoids the influence of chemical anti-fouling coatings on the biological activity of the ECL sensor. At the same time, electro-polymerized polyaniline nanowires are embedded in the anti-fouling erythrocyte membrane, enhancing its chemical stability and conductivity, thereby expanding the application of anti-fouling cell membranes in ECL analysis. C<subgt;3< / subgt;N<subgt;4< / subgt; is introduced as an internal standard to eliminate background signals and external interferences, so as to improve the detection accuracy of the biosensor. Based on this, the constructed ECL anti-fouling biosensor achieves ultrasensitive detection of human breast cancer cells MCF-7 in human serum, with a detection limit as low as 3 cells / mL.

The invention provides application of mitochondrial vesicles in reduction of mitochondrial DNA deletion mutation. The mitochondrial vesicles are prepared by wrapping mitochondria with erythrocyte membranes, the mitochondrial vesicles can be tested and verified to effectively reduce the mitochondrial DNA deletion mutation level in cells, metabolism and functions of mutant cells are improved, verification is further carried out in muscle cells of CPEO patients, and the clinical application prospect is wide. By implanting the mitochondrial vesicles, the mitochondrial DNA deletion mutation level in the CPEO patient muscle cells can be effectively reduced, which indicates that the mitochondrial vesicles have the potential of treating CPEO, and a new thought is provided for treating diseases related to mitochondrial DNA deletion mutation.

The present invention discloses an erythrocyte membrane nanodisc, a preparation method, and its application in assisted phototherapy. The erythrocyte membrane nanodisc comprises an erythrocyte membrane, a photosensitizing agent loaded onto the erythrocyte membrane, and a restrictor wrapped around the erythrocyte membrane, the restrictor being used to stabilize the morphology of the erythrocyte membrane. The erythrocyte membrane nanodisc is used in assisted phototherapy to enhance the permeability of the photosensitizing agent. The preparation method includes steps S1: obtaining an erythrocyte membrane; S2: loading the photosensitizing agent onto the erythrocyte membrane; and S3: wrapping the restrictor around the erythrocyte membrane to form a nanodisc. This solution can enhance the permeability of the photosensitizing agent by loading the nanodisc with the photosensitizing agent, thereby enhancing the phototherapy effect.

The invention discloses a blood type reverse typing reagent, a preparation method thereof and a blood type reverse typing detection kit. The method comprises the following steps: S1, constructing functional magnetic nanoparticles for expressing recombinant protein G; s2, preparing erythrocyte membrane antigen magnetic nanoparticles: adding an anti-H blood group monoclonal antibody into red blood cells, washing, splitting the red blood cells, adding the functionalized magnetic nanoparticles, washing, magnetically attracting, and freeze-drying a magnetic product to obtain the blood group reverse typing reagent. By utilizing the advantages of excellent magnetic properties and biocompatibility of magnetosomes and a surface display technology, protein G is expressed on the surfaces of the magnetosomes through genetic engineering and is specifically combined with an anti-H blood group antigen monoclonal antibody, and erythrocyte membrane antigens are coupled to the surfaces of the magnetosomes to form erythrocyte membrane antigen magnetic nanoparticles; and the problems of easy hemolysis of red blood cells and disappearance of red cell membrane antigens after long-time storage can be avoided. The magnetosome not only serves as a carrier of the antigen, but also serves as an indicator of the agglutination result, and result interpretation is facilitated.

The invention relates to the technical field of antibody drugs, in particular to a human recombinant single-chain antibody, nano-particles, a nano-drug composition and application of the human recombinant single-chain antibody, the nano-particles and the nano-drug composition. The invention provides a human recombinant single-chain antibody of specific anti-PHD2. The amino acid sequence of the human recombinant single-chain antibody is as shown in SEQ ID NO: 2. The obtained human recombinant single-chain antibody is more stable than INP and has good organ and tissue targeting. The human recombinant single-chain antibody is combined with meso-porous silicon nanoparticles and an erythrocyte membrane to prepare a nano-drug composition, and the nano-drug composition has a better effect of treating diseases.

The invention belongs to the technical field of tumor drugs, and particularly relates to an intelligent nano bionic drug delivery system based on ZIF-8, a preparation method and application, adriamycin, DNAzyme and an aptamer are loaded on ZIF-8, and the preparation method comprises the steps that after adriamycin is loaded to a ZIF-8 nano carrier, DNAzyme is further adsorbed by means of electrostatic interaction, and the ZIF-8 nano carrier is loaded with the DNAzyme; the intelligent nano bionic drug delivery system based on ZIF-8 is characterized in that a DOX / Dz-coated ZIF-8-RM / Apt nano drug delivery system is prepared by using a DOX / Dz-coated ZIF-8-RM / Apt nano drug delivery system, then using an erythrocyte membrane to perform surface modification, and finally inserting an aptamer drug into the surface of the cytomembrane through a lipid insertion method, and the intelligent nano bionic drug delivery system based on ZIF-8 is used for relieving chemotherapy drug resistance and improving the anti-tumor immunity efficiency; and the effect of the medicine in the tumor is improved to the greatest extent.

The invention provides application of lipid as a marker in preparation of a product for diagnosis or auxiliary diagnosis of Alzheimer's disease and / or mild cognitive impairment. The invention also provides an application of a substance for extracting lipid or a substance for detecting the expression level of lipid in preparation of a product for diagnosis or auxiliary diagnosis of Alzheimer's disease and / or mild cognitive impairment. The lipid is one or a combination of more of DAG 38: 2, TAG (14: 0 / 24: 1 (15Z) / 20: 0), TAG 58: 2, TAG 55: 5, TAG 53: 1, TAG 49: 3, TAG 45: 2, TAG 43: 1, PS 42: 8, PI (22: 1 (11Z) / 14: 0), PI (18: 2 (9Z, 12Z) / 18: 1 (9Z)), PC (22: 5 (7Z, 10Z, 13Z, 16Z, 19Z) / 18: 0), LPC (24: 1 (15Z The substance for extracting the lipid is a combination of isopropanol and a mixture of isopropanol, acetonitrile and water in a volume ratio of 4: 3: 1. In the extraction of the lipid difference substances, the red cell membrane (RCM) is creatively used as an extraction object, an extraction method is provided for the lipid difference substances of AD in the red cell membrane, 15 potential AD biological diagnosis markers are finally determined, and lipids prompt chronic physiological changes and are closely related to the pathogenesis of AD.

The present invention discloses a method for preparing a highly targeted liver cancer contrast agent, comprising the following steps: (1) encapsulating a quantum dot mixture with Ti3C2MXenes, wherein the quantum dot complex is composed of carbon quantum dots and graphyne quantum dots in a weight ratio of 1:1-2; (2) preparing a suspension from the product obtained in step (1), adding a hybrid cell membrane and homogenizing the suspension to obtain a highly targeted liver cancer contrast agent; the hybrid cell membrane is composed of erythrocyte membrane and macrophage membrane in a membrane protein weight ratio of 1:1, and the weight ratio of the product obtained in step (1) to the hybrid cell membrane is 3:1. The liver cancer contrast agent obtained by the invention has high dispersion stability and can be stored in an aqueous solution for more than 60 days. At the same time, at a low dosage of 0.5 μg / mL, the photoacoustic signal PA value can reach more than 1 within 24 hours. Moreover, the contrast agent obtained by the present invention has excellent targeting, with a targeting efficiency of up to 32% for liver cancer tumors.